You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 108 No. 9, September 1990 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  CLINICAL SCIENCES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

A Randomized Trial of Sorbinil, an Aldose Reductase Inhibitor, in Diabetic Retinopathy

Sorbinil Retinopathy Trial Research Group

Arch Ophthalmol. 1990;108(9):1234-1244.


Abstract



• A total of 497 patients aged 18 to 56 years with insulin-dependent diabetes mellitus for 1 to 15 years were randomly assigned to take oral sorbinil or placebo and followed up for a median of 41 months. The percentage of patients whose retinopathy severity grade at maximum follow-up had worsened by two or more levels was not significantly different between the two treatment groups (28% in the sorbinil group and 32% in the placebo group, P =.344). The number of microaneurysms increased at a slightly slower rate in the sorbinil group than in the placebo group, with statistically significant differences at 21 (P =.046) and 30 (P =.039) months but not at the maximum follow-up (P =.156). About 7% of the patients assigned sorbinil developed a hypersensitivity reaction in the first 3 months. On the basis of these results, it is unlikely that sorbinil administered at a dosage of 250 mg daily for 3 years has a clinically important effect on the course of retinopathy in adults with insulin-dependent diabetes of moderate duration. Our data are consistent, however, with a slightly slower progression rate in the microaneurysm count among patients assigned to take sorbinil, a finding of uncertain clinical importance.



Footnotes



Accepted for publication July 10, 1990.

A complete list of the collaborators in this study appears on page 1242.

Reprint requests to 55 Pond Ave, Brookline, MA 02146 (Dr Hennekens).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Comparability of Digital Photography with the ETDRS Film Protocol for Evaluation of Diabetic Retinopathy Severity
Li et al.
IOVS 2011;52:4717-4725.
ABSTRACT | FULL TEXT  

Role of the Polyol Pathway in High Glucose-Induced Apoptosis of Retinal Pericytes and Proliferation of Endothelial Cells
Takamura et al.
IOVS 2008;49:3216-3223.
ABSTRACT | FULL TEXT  

Intravitreal Injection of Erythropoietin Protects both Retinal Vascular and Neuronal Cells in Early Diabetes
Zhang et al.
IOVS 2008;49:732-742.
ABSTRACT | FULL TEXT  

Management of Diabetic Retinopathy: A Systematic Review
Mohamed et al.
JAMA 2007;298:902-916.
ABSTRACT | FULL TEXT  

A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy.
Sun et al.
Diabetes 2006;55:2757-2762.
ABSTRACT | FULL TEXT  

Analysis of glucose metabolism in diabetic rat retinas
Ola et al.
Am. J. Physiol. Endocrinol. Metab. 2006;290:E1057-E1067.
ABSTRACT | FULL TEXT  

Diabetic Retinopathy
Fong et al.
Diabetes Care 2004;27:2540-2553.
FULL TEXT  

Studies of Rat and Human Retinas Predict a Role for the Polyol Pathway in Human Diabetic Retinopathy
Dagher et al.
Diabetes 2004;53:2404-2411.
ABSTRACT | FULL TEXT  

Relation between intake of vitamins C and E and risk of diabetic retinopathy in the Atherosclerosis Risk in Communities Study
Millen et al.
Am J Clin Nutr 2004;79:865-873.
ABSTRACT | FULL TEXT  

Effects of Aldose Reductase Inhibitors and Galactose Withdrawal on Fluorescein Angiographic Lesions in Galactose-Fed Dogs
Cusick et al.
Arch Ophthalmol 2003;121:1745-1751.
ABSTRACT | FULL TEXT  

Biochemical Pathways for Microvascular Complications of Diabetes Mellitus
Setter et al.
The Annals of Pharmacotherapy 2003;37:1858-1866.
ABSTRACT | FULL TEXT  

Effect of Intravenous Administration of Sodium-Lactate on Retinal Blood Flow in Healthy Subjects
Garhofer et al.
IOVS 2003;44:3972-3976.
ABSTRACT | FULL TEXT  

Diabetic Retinopathy and Diabetic Macular Edema: Pathophysiology, screening, and novel therapies
Ciulla et al.
Diabetes Care 2003;26:2653-2664.
ABSTRACT | FULL TEXT  

A Role for the Polyol Pathway in the Early Neuroretinal Apoptosis and Glial Changes Induced by Diabetes in the Rat
Asnaghi et al.
Diabetes 2003;52:506-511.
ABSTRACT | FULL TEXT  

Correlation between erythrocyte aldose reductase level and human diabetic retinopathy
Oishi et al.
Br J Ophthalmol 2002;86:1363-1366.
ABSTRACT | FULL TEXT  

Molecular Understanding of Hyperglycemia's Adverse Effects for Diabetic Complications
Sheetz and King
JAMA 2002;288:2579-2588.
ABSTRACT | FULL TEXT  

Review: Thirty-seven years with diabetic retinopathy
Kohner
British Journal of Diabetes & Vascular Disease 2002;2:452-456.
ABSTRACT  

Pharmacological Inhibition of Diabetic Retinopathy: Aminoguanidine and Aspirin
Kern and Engerman
Diabetes 2001;50:1636-1642.
ABSTRACT | FULL TEXT  

Interval Between Onset of Mild Nonproliferative and Proliferative Retinopathy in Type I Diabetes
Vitale et al.
Arch Ophthalmol 1997;115:194-198.
ABSTRACT  

Metabolic cataracts in newly diagnosed diabetes
Datta et al.
Arch. Dis. Child. 1997;76:118-120.
ABSTRACT | FULL TEXT  

The Galactosemic Dog: A Valid Model for Both Early and Late Stages of Diabetic Retinopathy
Frank
Arch Ophthalmol 1995;113:275-276.
ABSTRACT  

10 Years: Over 10 000 Manuscripts
Goldberg
Arch Ophthalmol 1994;112:749-751.
ABSTRACT  

The Treatment of Diabetic Retinopathy: A View for the Internist
Raskin and Arauz-Pacheco
ANN INTERN MED 1992;117:226-233.
ABSTRACT  

Aldose Reductase Inhibition: The Chemical Key to the Control of Diabetic Retinopathy?
Frank
Arch Ophthalmol 1990;108:1229-1231.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.